Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency

Drug Saf. 2023 Mar;46(3):319-321. doi: 10.1007/s40264-023-01275-7. Epub 2023 Feb 14.
No abstract available

Publication types

  • Letter

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Humans
  • Product Surveillance, Postmarketing
  • SARS-CoV-2
  • Sweden / epidemiology
  • Vaccination
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines